Mosoka Papa Fallah, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hemorrhagic Fever, Ebola | 59 | 2024 | 419 | 13.170 |
Why?
|
Ebolavirus | 21 | 2023 | 247 | 4.210 |
Why?
|
Liberia | 48 | 2023 | 174 | 3.630 |
Why?
|
Epidemics | 15 | 2024 | 512 | 3.290 |
Why?
|
Disease Outbreaks | 29 | 2024 | 1747 | 2.990 |
Why?
|
Survivors | 8 | 2021 | 2369 | 1.330 |
Why?
|
Africa | 15 | 2024 | 714 | 1.220 |
Why?
|
Ebola Vaccines | 3 | 2023 | 24 | 1.200 |
Why?
|
Contact Tracing | 7 | 2023 | 272 | 0.840 |
Why?
|
Financial Management | 1 | 2022 | 160 | 0.740 |
Why?
|
Dengue | 1 | 2024 | 254 | 0.720 |
Why?
|
Uveitis | 3 | 2021 | 396 | 0.660 |
Why?
|
Pregnancy Outcome | 2 | 2023 | 2923 | 0.660 |
Why?
|
Community Health Services | 4 | 2019 | 654 | 0.650 |
Why?
|
Malaria | 2 | 2024 | 1225 | 0.580 |
Why?
|
Cholera | 1 | 2024 | 747 | 0.580 |
Why?
|
Scabies | 3 | 2021 | 14 | 0.560 |
Why?
|
Social Stigma | 2 | 2021 | 770 | 0.520 |
Why?
|
Africa, Western | 7 | 2024 | 159 | 0.510 |
Why?
|
Eye Diseases | 1 | 2021 | 653 | 0.490 |
Why?
|
Trust | 1 | 2019 | 529 | 0.470 |
Why?
|
Anti-Retroviral Agents | 1 | 2022 | 1784 | 0.400 |
Why?
|
Pandemics | 6 | 2024 | 8663 | 0.400 |
Why?
|
Vaccination | 7 | 2024 | 3369 | 0.380 |
Why?
|
Urban Population | 2 | 2020 | 2036 | 0.370 |
Why?
|
Clinical Protocols | 1 | 2017 | 1436 | 0.370 |
Why?
|
Lassa virus | 2 | 2021 | 98 | 0.340 |
Why?
|
Lassa Fever | 2 | 2021 | 96 | 0.330 |
Why?
|
Toll-Like Receptor 2 | 1 | 2011 | 344 | 0.320 |
Why?
|
Rural Population | 2 | 2020 | 2277 | 0.310 |
Why?
|
Neisseria meningitidis, Serogroup C | 2 | 2018 | 11 | 0.310 |
Why?
|
Humans | 87 | 2024 | 761208 | 0.310 |
Why?
|
Meningitis, Meningococcal | 2 | 2018 | 43 | 0.300 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 3200 | 0.300 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1212 | 0.300 |
Why?
|
Delivery of Health Care | 5 | 2021 | 5333 | 0.300 |
Why?
|
Toll-Like Receptor 4 | 1 | 2011 | 577 | 0.290 |
Why?
|
Semen | 3 | 2021 | 347 | 0.280 |
Why?
|
Population Surveillance | 2 | 2017 | 2598 | 0.280 |
Why?
|
Communicable Disease Control | 4 | 2021 | 846 | 0.270 |
Why?
|
Poverty | 3 | 2023 | 2691 | 0.270 |
Why?
|
Spleen | 2 | 2014 | 2290 | 0.260 |
Why?
|
Developing Countries | 1 | 2018 | 2863 | 0.250 |
Why?
|
Health Services Accessibility | 3 | 2022 | 5425 | 0.250 |
Why?
|
Drug Storage | 1 | 2024 | 52 | 0.230 |
Why?
|
Drug Stability | 1 | 2024 | 288 | 0.220 |
Why?
|
Pain | 1 | 2019 | 5072 | 0.220 |
Why?
|
Growth and Development | 1 | 2023 | 46 | 0.220 |
Why?
|
Malaria Vaccines | 1 | 2024 | 163 | 0.210 |
Why?
|
Filoviridae | 2 | 2019 | 15 | 0.200 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2011 | 2455 | 0.200 |
Why?
|
Logic | 1 | 2022 | 40 | 0.200 |
Why?
|
Longitudinal Studies | 4 | 2023 | 14610 | 0.190 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2011 | 2864 | 0.190 |
Why?
|
RNA, Viral | 3 | 2021 | 2839 | 0.190 |
Why?
|
Medicine, African Traditional | 1 | 2021 | 31 | 0.190 |
Why?
|
Antiparasitic Agents | 1 | 2021 | 42 | 0.190 |
Why?
|
Democratic Republic of the Congo | 2 | 2018 | 86 | 0.190 |
Why?
|
Color Vision Defects | 1 | 2021 | 28 | 0.180 |
Why?
|
Emergencies | 2 | 2024 | 1217 | 0.180 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2022 | 219 | 0.170 |
Why?
|
Infant | 6 | 2023 | 36169 | 0.170 |
Why?
|
Mass Vaccination | 1 | 2021 | 109 | 0.170 |
Why?
|
Quarantine | 1 | 2022 | 182 | 0.170 |
Why?
|
Filoviridae Infections | 1 | 2019 | 6 | 0.170 |
Why?
|
HIV Infections | 3 | 2022 | 17347 | 0.160 |
Why?
|
Public Health Administration | 1 | 2021 | 242 | 0.160 |
Why?
|
Measles Vaccine | 1 | 2019 | 79 | 0.160 |
Why?
|
Emigration and Immigration | 2 | 2018 | 397 | 0.160 |
Why?
|
Public Health | 5 | 2024 | 2672 | 0.150 |
Why?
|
Diagnostic Tests, Routine | 2 | 2022 | 788 | 0.150 |
Why?
|
Thailand | 1 | 2019 | 287 | 0.150 |
Why?
|
Immunoassay | 2 | 2019 | 743 | 0.150 |
Why?
|
Medical Tourism | 1 | 2018 | 52 | 0.150 |
Why?
|
Adolescent | 16 | 2021 | 88298 | 0.150 |
Why?
|
Uganda | 1 | 2022 | 1332 | 0.150 |
Why?
|
Climate Change | 1 | 2024 | 498 | 0.140 |
Why?
|
Macrophages | 2 | 2014 | 5753 | 0.140 |
Why?
|
Measles | 1 | 2019 | 181 | 0.140 |
Why?
|
Mobile Health Units | 1 | 2018 | 92 | 0.140 |
Why?
|
Health Communication | 2 | 2017 | 213 | 0.140 |
Why?
|
Macular Edema | 1 | 2021 | 374 | 0.140 |
Why?
|
Female | 27 | 2023 | 392544 | 0.140 |
Why?
|
World Health Organization | 2 | 2021 | 1321 | 0.140 |
Why?
|
Immunization Programs | 1 | 2019 | 267 | 0.130 |
Why?
|
South Africa | 1 | 2022 | 1843 | 0.130 |
Why?
|
Culture | 1 | 2020 | 623 | 0.130 |
Why?
|
International Agencies | 1 | 2017 | 244 | 0.130 |
Why?
|
Adult | 20 | 2021 | 221119 | 0.130 |
Why?
|
Cytokines | 1 | 2011 | 7386 | 0.130 |
Why?
|
Models, Statistical | 3 | 2022 | 5081 | 0.130 |
Why?
|
Fatigue | 2 | 2022 | 1550 | 0.130 |
Why?
|
Memory Disorders | 2 | 2022 | 1198 | 0.130 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2018 | 250 | 0.120 |
Why?
|
Residence Characteristics | 2 | 2015 | 2092 | 0.120 |
Why?
|
Disaster Planning | 1 | 2021 | 557 | 0.120 |
Why?
|
Intraocular Pressure | 1 | 2021 | 1294 | 0.120 |
Why?
|
Cicatrix | 1 | 2021 | 793 | 0.120 |
Why?
|
Financial Support | 1 | 2015 | 116 | 0.120 |
Why?
|
Pregnancy | 4 | 2023 | 29893 | 0.120 |
Why?
|
Stochastic Processes | 1 | 2015 | 355 | 0.120 |
Why?
|
Dogs | 1 | 2019 | 3832 | 0.120 |
Why?
|
Leishmania major | 1 | 2014 | 59 | 0.110 |
Why?
|
Child | 13 | 2020 | 80152 | 0.110 |
Why?
|
Placenta | 1 | 2023 | 1711 | 0.110 |
Why?
|
Guinea | 3 | 2018 | 33 | 0.110 |
Why?
|
Health Resources | 1 | 2020 | 934 | 0.110 |
Why?
|
Meglumine | 1 | 2014 | 144 | 0.110 |
Why?
|
Antiprotozoal Agents | 1 | 2014 | 94 | 0.110 |
Why?
|
Antibodies, Viral | 3 | 2019 | 3149 | 0.110 |
Why?
|
Male | 23 | 2021 | 360693 | 0.110 |
Why?
|
Stillbirth | 1 | 2016 | 369 | 0.110 |
Why?
|
Cohort Studies | 5 | 2023 | 41496 | 0.110 |
Why?
|
Live Birth | 1 | 2016 | 511 | 0.100 |
Why?
|
Young Adult | 12 | 2021 | 59221 | 0.100 |
Why?
|
Vaccines | 1 | 2021 | 835 | 0.100 |
Why?
|
International Cooperation | 2 | 2017 | 1423 | 0.100 |
Why?
|
Antibodies, Neutralizing | 2 | 2019 | 1935 | 0.100 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 2014 | 136 | 0.100 |
Why?
|
Viral Load | 2 | 2019 | 3328 | 0.100 |
Why?
|
Aging | 1 | 2011 | 8702 | 0.100 |
Why?
|
Resilience, Psychological | 1 | 2020 | 788 | 0.100 |
Why?
|
Asymptomatic Infections | 2 | 2023 | 131 | 0.100 |
Why?
|
Cost of Illness | 1 | 2021 | 1936 | 0.100 |
Why?
|
Models, Economic | 1 | 2015 | 714 | 0.100 |
Why?
|
Abortion, Spontaneous | 1 | 2016 | 533 | 0.090 |
Why?
|
Immunoglobulin G | 1 | 2023 | 4537 | 0.090 |
Why?
|
Pregnant Women | 1 | 2016 | 568 | 0.090 |
Why?
|
Glycoproteins | 1 | 2019 | 2203 | 0.090 |
Why?
|
Child, Preschool | 6 | 2020 | 42224 | 0.090 |
Why?
|
Headache | 1 | 2019 | 1255 | 0.090 |
Why?
|
Organometallic Compounds | 1 | 2014 | 647 | 0.090 |
Why?
|
Models, Theoretical | 3 | 2020 | 3571 | 0.090 |
Why?
|
Infant, Newborn | 2 | 2023 | 26199 | 0.090 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 26071 | 0.090 |
Why?
|
Health Facilities | 1 | 2015 | 575 | 0.090 |
Why?
|
Genome, Viral | 3 | 2019 | 665 | 0.090 |
Why?
|
Logistic Models | 3 | 2020 | 13249 | 0.090 |
Why?
|
Cluster Analysis | 4 | 2017 | 2706 | 0.080 |
Why?
|
Prenatal Care | 1 | 2016 | 1141 | 0.080 |
Why?
|
Middle Aged | 14 | 2021 | 220853 | 0.080 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2015 | 1372 | 0.070 |
Why?
|
Signal Transduction | 1 | 2011 | 23416 | 0.070 |
Why?
|
Infection Control | 1 | 2015 | 983 | 0.070 |
Why?
|
Tomography, Optical Coherence | 1 | 2021 | 2923 | 0.070 |
Why?
|
Mental Health | 1 | 2021 | 3251 | 0.070 |
Why?
|
Health Services Needs and Demand | 1 | 2015 | 1401 | 0.070 |
Why?
|
Social Class | 1 | 2015 | 1993 | 0.070 |
Why?
|
Odds Ratio | 1 | 2019 | 9652 | 0.070 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2015 | 1074 | 0.070 |
Why?
|
Incidence | 4 | 2021 | 21365 | 0.070 |
Why?
|
Mice, Inbred BALB C | 2 | 2014 | 6199 | 0.070 |
Why?
|
Vulnerable Populations | 2 | 2021 | 706 | 0.060 |
Why?
|
Streptococcus pneumoniae | 1 | 2011 | 730 | 0.060 |
Why?
|
Sierra Leone | 2 | 2016 | 169 | 0.060 |
Why?
|
Patient Isolation | 2 | 2016 | 100 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2017 | 4014 | 0.060 |
Why?
|
Qualitative Research | 3 | 2021 | 3024 | 0.060 |
Why?
|
Health Policy | 1 | 2017 | 2679 | 0.060 |
Why?
|
Health Personnel | 4 | 2020 | 3337 | 0.050 |
Why?
|
Anthropology, Cultural | 1 | 2024 | 102 | 0.050 |
Why?
|
Communication | 3 | 2024 | 3872 | 0.050 |
Why?
|
Focus Groups | 2 | 2020 | 1413 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3093 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3215 | 0.050 |
Why?
|
Pilot Projects | 3 | 2023 | 8642 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2019 | 9187 | 0.050 |
Why?
|
Ivermectin | 1 | 2021 | 46 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 3803 | 0.050 |
Why?
|
Impetigo | 1 | 2020 | 7 | 0.050 |
Why?
|
Tropical Medicine | 1 | 2021 | 51 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2019 | 22174 | 0.050 |
Why?
|
Neglected Diseases | 1 | 2021 | 66 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 14675 | 0.040 |
Why?
|
History, 21st Century | 2 | 2017 | 1567 | 0.040 |
Why?
|
Lymphocyte Activation | 1 | 2011 | 5478 | 0.040 |
Why?
|
Aged | 6 | 2019 | 169288 | 0.040 |
Why?
|
Dermoscopy | 1 | 2020 | 66 | 0.040 |
Why?
|
N-Acetylglucosaminyltransferases | 1 | 2021 | 166 | 0.040 |
Why?
|
Community Health Planning | 1 | 2020 | 164 | 0.040 |
Why?
|
Prevalence | 3 | 2021 | 15721 | 0.040 |
Why?
|
Government Programs | 1 | 2021 | 278 | 0.040 |
Why?
|
Registries | 1 | 2015 | 8247 | 0.040 |
Why?
|
Capacity Building | 1 | 2021 | 259 | 0.040 |
Why?
|
Likelihood Functions | 1 | 2022 | 991 | 0.040 |
Why?
|
Antibodies, Blocking | 1 | 2019 | 249 | 0.040 |
Why?
|
Prospective Studies | 1 | 2023 | 54435 | 0.040 |
Why?
|
Multilocus Sequence Typing | 1 | 2018 | 101 | 0.040 |
Why?
|
Vero Cells | 1 | 2019 | 482 | 0.040 |
Why?
|
Risk Factors | 4 | 2018 | 74239 | 0.040 |
Why?
|
Nigeria | 1 | 2021 | 771 | 0.040 |
Why?
|
Anticonvulsants | 1 | 2008 | 1910 | 0.040 |
Why?
|
Time Factors | 2 | 2017 | 39957 | 0.040 |
Why?
|
Behavior Therapy | 1 | 2024 | 875 | 0.040 |
Why?
|
Arthralgia | 1 | 2022 | 461 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2019 | 399 | 0.040 |
Why?
|
Receptors, Virus | 1 | 2021 | 642 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2011 | 4744 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2018 | 58952 | 0.040 |
Why?
|
Multiple Myeloma | 1 | 2015 | 5145 | 0.040 |
Why?
|
Neutralization Tests | 1 | 2019 | 725 | 0.040 |
Why?
|
Attitude | 1 | 2021 | 771 | 0.030 |
Why?
|
Molecular Epidemiology | 1 | 2018 | 470 | 0.030 |
Why?
|
Microspheres | 1 | 2019 | 783 | 0.030 |
Why?
|
Limit of Detection | 1 | 2017 | 273 | 0.030 |
Why?
|
Probability | 1 | 2021 | 2478 | 0.030 |
Why?
|
Case Management | 1 | 2018 | 272 | 0.030 |
Why?
|
Occupational Exposure | 2 | 2017 | 1814 | 0.030 |
Why?
|
Serologic Tests | 1 | 2018 | 381 | 0.030 |
Why?
|
United States | 1 | 2024 | 72339 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2015 | 6919 | 0.030 |
Why?
|
Metagenomics | 1 | 2018 | 463 | 0.030 |
Why?
|
Immunization | 1 | 2019 | 1218 | 0.030 |
Why?
|
Community-Based Participatory Research | 1 | 2017 | 221 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10088 | 0.030 |
Why?
|
Genotype | 2 | 2019 | 12985 | 0.030 |
Why?
|
Mass Media | 1 | 2017 | 303 | 0.030 |
Why?
|
Educational Status | 1 | 2021 | 2510 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2011 | 11509 | 0.030 |
Why?
|
Laboratories | 1 | 2017 | 462 | 0.030 |
Why?
|
Research | 1 | 2021 | 1976 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11101 | 0.030 |
Why?
|
Animals | 5 | 2019 | 168079 | 0.030 |
Why?
|
Epilepsy | 1 | 2008 | 3304 | 0.030 |
Why?
|
Models, Psychological | 1 | 2017 | 830 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2020 | 2697 | 0.030 |
Why?
|
Viral Vaccines | 1 | 2018 | 593 | 0.030 |
Why?
|
Demography | 1 | 2017 | 1641 | 0.030 |
Why?
|
Sweden | 1 | 2015 | 1379 | 0.030 |
Why?
|
Sex Distribution | 1 | 2017 | 2277 | 0.020 |
Why?
|
Administration, Topical | 1 | 2014 | 703 | 0.020 |
Why?
|
Plasma Cells | 1 | 2015 | 597 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2023 | 5250 | 0.020 |
Why?
|
Disease Progression | 2 | 2022 | 13511 | 0.020 |
Why?
|
Phylogeny | 1 | 2019 | 2809 | 0.020 |
Why?
|
Community-Acquired Infections | 1 | 2016 | 469 | 0.020 |
Why?
|
Age Distribution | 1 | 2017 | 2871 | 0.020 |
Why?
|
Morbidity | 1 | 2016 | 1751 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2021 | 4243 | 0.020 |
Why?
|
Maternal Health Services | 1 | 2016 | 460 | 0.020 |
Why?
|
Liposomes | 1 | 2014 | 783 | 0.020 |
Why?
|
Health Services | 1 | 2015 | 750 | 0.020 |
Why?
|
Random Allocation | 1 | 2014 | 2393 | 0.020 |
Why?
|
Licensure, Pharmacy | 1 | 2008 | 2 | 0.020 |
Why?
|
Nipecotic Acids | 1 | 2008 | 36 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 20982 | 0.020 |
Why?
|
Mice | 2 | 2014 | 81326 | 0.020 |
Why?
|
Piracetam | 1 | 2008 | 88 | 0.020 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2008 | 140 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10218 | 0.020 |
Why?
|
Half-Life | 1 | 2008 | 649 | 0.020 |
Why?
|
Finland | 1 | 2008 | 607 | 0.020 |
Why?
|
Cross Infection | 1 | 2016 | 1422 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8457 | 0.020 |
Why?
|
Amines | 1 | 2008 | 280 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6345 | 0.020 |
Why?
|
Triazines | 1 | 2008 | 311 | 0.020 |
Why?
|
Fructose | 1 | 2008 | 285 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2015 | 2731 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 2507 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9616 | 0.020 |
Why?
|
Mortality | 1 | 2016 | 2896 | 0.020 |
Why?
|
Family | 1 | 2015 | 3192 | 0.010 |
Why?
|
Hospitalization | 1 | 2024 | 10707 | 0.010 |
Why?
|
Genomics | 1 | 2019 | 5828 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7804 | 0.010 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2008 | 1139 | 0.010 |
Why?
|
Risk Assessment | 1 | 2023 | 24021 | 0.010 |
Why?
|
Mass Screening | 1 | 2017 | 5426 | 0.010 |
Why?
|
Retrospective Studies | 3 | 2016 | 80674 | 0.010 |
Why?
|
Prognosis | 1 | 2021 | 29687 | 0.010 |
Why?
|
Skin | 1 | 2014 | 4473 | 0.010 |
Why?
|
Cell Line | 1 | 2014 | 15545 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39126 | 0.010 |
Why?
|
Quality of Life | 1 | 2020 | 13367 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 17897 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2008 | 64681 | 0.000 |
Why?
|